Drug Channels Archive for May, 2024

Click a link below to view the mailing archive as if it had been sent to you.

2024-05-31 07:47		Drug Channels - Shifting Strategies: Tackling Patient Support Program Reverification
2024-05-29 07:47		Drug Channels News Roundup, May 2024: CVS & Cordavis & Humira, 340Boom, AFP Slowdown, Asembia Wrap-Up, and GLP-1 Humor
2024-05-22 07:47		Drug Channels - Why the IRA Will Encourage Part D Plans to Prefer High-List, High-Rebate Drugs (video)
2024-05-21 07:47		Drug Channels - The 340B Drug Pricing Program: Trends, Controversies, and Outlook (NEW Live Video Webinar)
2024-05-17 07:47		Drug Channels - HCP Perspectives: Access Challenges in Treating Diabetes & Obesity
2024-05-14 07:47		Drug Channels - Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs
2024-05-10 07:47		Drug Channels - Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers
2024-05-07 07:47		Drug Channels - Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A May 2024 Update
2024-05-03 07:47		Drug Channels - Bracing for Impact: The Future of Hub, PAP, and Affordability Programs Under the Inflation Reduction Act
2024-05-01 07:47		Drug Channels News Roundup, April 2024: CVS's Humira Strategy, White Bagging “Savings,” IRA vs. Part D Plans, Walgreens Specialty Update, Pharmacies vs. GoodRx, and Oncology Fun